Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11814849 | 0.95 | KEAP1 (0.41) | KEAP1NFE2L2ALDH1A1TSHREPHX1 | |
| SCHEMBL1733953 | 0.92 | EPHX1 (0.39) | KEAP1NFE2L2ALDH1A1TSHREPHX1 | |
| SCHEMBL28314636 | 0.90 | EPHX1 (0.38) | KEAP1NFE2L2ALDH1A1TSHREPHX1 | |
| SCHEMBL21269303 | 0.90 | EPHX1 (0.38) | KEAP1NFE2L2ALDH1A1TSHREPHX1 | |
| SCHEMBL21269436 | 0.90 | EPHX1 (0.38) | KEAP1NFE2L2ALDH1A1TSHREPHX1 | |
| SCHEMBL28314811 | 0.90 | EPHX1 (0.38) | KEAP1NFE2L2ALDH1A1TSHREPHX1 | |
| SCHEMBL21269775 | 0.90 | EPHX1 (0.38) | KEAP1NFE2L2ALDH1A1TSHREPHX1 | |
| SCHEMBL28314566 | 0.90 | EPHX1 (0.38) | KEAP1NFE2L2ALDH1A1TSHREPHX1 | |
| SCHEMBL1427209 | 0.89 | TSHR (0.40) | KEAP1NFE2L2ALDH1A1TSHREPHX1 | |
| SCHEMBL28315747 | 0.88 | EPHX1 (0.37) | KEAP1NFE2L2ALDH1A1TSHREPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | HALE JEFFREY J (US) | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | CCR5, CCR1, CXCR1 | KEAP1 4472/4885NFE2L2 4664/4885ALDH1A1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.